CytomX Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

CytomX Therapeutics

07/05/2024 03:08

* CytomX Therapeutics Inc  CTMX.OQ   CTMX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 8 for
the period ending March 31 2024
    * The South San Francisco California-based  company is
expected to
report a 8.8% decrease in revenue to $21.435 million from $23.5
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for CytomX Therapeutics Inc
is for
a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 41.4%
in the last three months. ​
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $3.25​, below​ its last closing price
of $4.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.01        -0.03      0.01      Beat    135
 Sep. 30 2023  -0.15       -0.19      0.04      Beat    121.2
 Jun. 30 2023  -0.18       -0.20      -0.02     Beat    90.2​
 Mar. 31 2023  -0.12       -0.11      -0.05     Beat    52.7
 ​​Dec.        -0.17       -0.24      -0.43     Missed  -82.5
 31 2022                                                
 Sep. 30 2022  -0.29       -0.31      -0.35     Missed  -14.5​
 Jun. 30 2022  -0.36       -0.36      -0.37     Missed  -2.8
 Mar. 31 2022  -0.38       -0.36      -0.37     Missed  -1.8
 This summary was machine generated May 7 at 02:08 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)